The current coronavirus disease 2019 (COVID‐19) pandemic has produced an understandable sense of urgency among clinicians and researchers to develop, deploy, and report novel treatment strategies. Many centers are therefore using off‐label therapies and reporting early observational results of their experiences.(1‐3) A similar situation arose during the 2014 outbreak of Ebola virus disease (EVD).